Our new products range incorporates new products launched, new principals and an international focus. It reflects current emphasis to evolve into a one stop shop for high-end niche diagnostic solutions and research / biotechnology focus.
We are pleased to announce the availability of new diagnostic markers for sepsis and inflammation. Inflammation is the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. Inflammation is not a synonym for infection. Infection is caused by an exogenous pathogen, while inflammation is the response of the organism to the pathogen.
When inflammation overwhelms the host, systemic inflammatory response syndrome is diagnosed. When it is due to infection, the
term sepsis is applied, with bacteremia being applied specifically for bacterial sepsis and viremia specifically to viral sepsis.Vasodilation and organ dysfunction are serious problems associated with widespread infection that may lead to septic shock and death.
The Leuko64™ assay is innovative and highly specific concept intended for use in the measurement of leukocyte neutrophil CD64 levels, which increase in response to infection or tissue injury
With the Leuko64™ kit a procedure for the diagnosis of early-onset of inflammation and sepsis is available, that could direct an effective therapy at the right time and save unnecessary spending for critically ill patients.
Also available in our range of rheumatoid markers is a new marker – Anti CCP. Medizym® anti-CCP Ref is used for the quantitative determination of IgG antibodies against cyclic citrullinated peptides (CCP) in human sera. Rheumatoid Arthritis (RA) is most often diagnosed by the measurement of rheumatoid factors (RF). The rheumatoid factor is an antibody directed against the Fc-region of IgG. It appears mainly as IgM antibody but also as IgA or IgG subgroup.
Rheumatoid factors are present in sera of 70 - 80 % of patients suffering from rheumatoid arthritis. But it is not specific for RA since it will also be found in healthy persons. The incidence depends on the age: for young people it is 1 - 4 %, for older persons it may reach up to 25 %. The advantage of CCP antibodies is a higher sensitivity and specificity for the diagnosis of rheumatoid arthritis in comparison to the rheumatoid factors alone. Anti-CCP is often found at a very early state of the disease and it has a high predictive value for development of the disease.
We are also increasing our presence in the cell culture segment with our addition of primary animal cells and new products including cell culture bags, supplements,
KineticBlue™ - cell viability / proliferation kits.
Our Custom services is a new introduction pooling our experience of five years to offer solutions to the diagnostic and research community.
|